.png){kind=icon}
.png){kind=icon}
Return
Beyond GLP-1: Amylin-Based Pharmacotherapy and the Search for Better-Tolerated Weight-Loss Drugs
.png){kind=icon}
OA
AI
S
T
DOI：10.1016/j.phrs.2026.108382.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Amylin-based therapies are emerging beyond GLP-1 obesity pharmacology • New amylin analogs may be better tolerated than GLP-1 therapies • AMYR/CTR selectivity may shape both weight-loss efficacy and tolerability • Hindbrain–parabrachial circuits may separate satiation from aversion • Long-acting amylin analogs differ in receptor kinetics and brain access
Keywords:
AMYR
Amylin receptor
AMY1R
Amylin receptor 1 (CTR + RAMP1)
AMY2R
Amylin receptor 2 (CTR + RAMP2)
AMY3R
Amylin receptor 3 (CTR + RAMP3)
AP
Area postrema
CFA
Conditioned flavor avoidance
CGRP
Calcitonin gene-related peptide
CNS
Central nervous system
CTR
Calcitonin receptor
DACRA
Dual amylin/calcitonin receptor agonist
DIO
Diet-induced obesity
FDA
Food and Drug Administration
GDF15
Growth differentiation factor 15
GFRAL
Glial cell line-derived neurotrophic factor family receptor alpha-like
GLP-1
Glucagon-like peptide-1
GLP-1R
Glucagon-like peptide-1 receptor
hAMY1R
Human amylin receptor 1
hAMY3R
Human amylin receptor 3
hCTR
Human calcitonin receptor
KO
Knockout
LPBN
Lateral parabrachial nucleus
NTS
Nucleus of the tractus solitarii
PBN
Parabrachial nucleus
RAMP
Receptor activity-modifying protein
RAMP1
Receptor activity-modifying protein 1
RAMP2
Receptor activity-modifying protein 2
RAMP3
Receptor activity-modifying protein 3
sCT
Salmon calcitonin
SNAC
Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate
Obesity pharmacotherapy
Amylin-based therapeutics
AMYR/CTR signaling
Nausea
Emesis
Hindbrain circuits
Tolerability Profile
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.5
Papers:
8.7K
Citations:
3.6W
Organization
Cited Papers